NTRK1 and non-small cell lung carcinoma: In addition, YD was found to be active against gefitinib-resistant non-small cell lung cancer (NSCLC) in mice, via the targeting of the AXL receptor tyrosine kinase, frequently overexpressed in NSCLC cells [71,72].